PE was reasonable.
Buy PE of 19.64 is above 10 years PE median of 15.07.
Earnings have been increasing since 2012.
Return on equity is good at 27%.
Debt is 892.10cr and ₹393.80cr cash.
The market cap of the company is ₹7,831.48cr.
Buy date: 21-Dec-2020
Qty: 29 Buy Price: ₹342.3 Buy EPS: 17.42 Buy PE: 19.64
The stock has fallen 10% but the earnings improved so I have added 32 shares.
Buy date: 18-Mar-2021
Qty: 32 Buy Price: ₹307.75 Buy EPS: 20.53 Buy PE: 15.85
Q4 results were released on May 11th and the current EPS is 22.18 which increased by 27.32% and 8.04% from my buy EPS.
The price of the stock is down about -2.4% from my average buy price.
Buy date: 12-May-2022
Qty: 41 Buy Price: ₹239 Buy EPS:₹17.15 Buy PE: 13.93
Buyback: 17-Oct-2022
Qty: 29 Sold Price: ₹400 Sold EPS:₹16.89 Sold PE: 23.68
Granules India is an India-based pharmaceutical company. The company manufactures active pharmaceutical ingredients, pharmaceutical formulation intermediates, and finished dosages. Its business is organized into three areas; the Core business which comprises core molecules such as Paracetamol, Ibuprofen, Metformin, Guaifenesin, and Methocarbamol; the emerging business focuses on manufacturing APIs and the US Generics. Its primary geographic markets are North America, Latin America, Europe, India, and the Rest of the World.
Disclaimer: The video is for educational purposes and for my friends and family. I am not a financial advisor and do not consider it as buy or sell. Taking advice from a random guy on the internet is harmful to your portfolio. I do not do a deep analysis of stocks I buy them just as a hobby.
No comments:
Post a Comment